The shareholders in Coala-Life Group AB (publ), reg. no. 556495-4682, are hereby given notice to attend an extraordinary general meeting at 10:00 a.m. on Thursday 26 January 2023 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting. The board of directors…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE ANY OTHER MEASURES THAN REQUIRED BY SWEDISH LAW. Coala-Life Group…
KPI’s October 2022: Patients in RPM as of October 31, 2022: 2,800 Annual revenue rate as of October 31, 2022: 3.2 MUSD Explanations of KPI’sPatients in RPM as of October 31, 2022 – Number of patients that the company monitors in USA at the end of October.Annual revenue rate as of October 31, 2022 –…
Third quarter 2022 Net sales increased to SEK 5.0 M (0.9). EBITDA amounted to SEK -27.8 M (-16.0). Operating income totaled SEK -28.2 M (-16.9). Profit after tax was SEK -18.5 M (-16.0). Earnings per share (weighted) was SEK -0.3 (-7.8). Cash flow from operating activities was SEK -36.0 M (-13.7). The period, January…
Coala-Life Group AB (publ) (”Coala Life” or ”The Company”) has entered into a loan facility agreement of SEK 25 M with a consortium of existing shareholder, to ensure that the Company has sufficient funds to meet the short-term working capital needs. The facility is available to the Company, to be utilized in its entirety, until…
Coala Life begins monthly reporting of Key Performance Indicators (KPI’s) for the company’s main market, USA. The KPI’s that will be reported monthly are; number of patients that the company monitors in USA at the end of each month, and estimated recurring revenue in USD based on the last month’s revenue, measured at an annual…
Second quarter 2022 Net sales increased to SEK 1.6 M (0.9). EBITDA totaled SEK -40.7 M (-9.0). Operating income totaled SEK -41.4 M (-9.8). Profit after tax was SEK -38.5 M (-9.8). Earnings per share was SEK -0.6 (-4.8). Cash flow from operating activities was SEK -50.9 M (-10.2). The period, January 1, 2022 –…
Coala Life has today completed the acquisition of Vitrics Management Group Inc for a purchase price of USD 3.5 million on a cash and debt-free basis. Vitrics is a fast-growing service company within Remote Patient Monitoring (RPM). The acquisition is in line with Coala Life’s strategy, with clear sales and operational synergies. On June 9…
Coala-Life Group AB (publ), has today entered into an agreement to acquire 100 percent of the shares in Vitrics Management Group Inc (“Vitrics”) for a purchase price of USD 4.5 million on a cash and debt-free basis. Vitrics is a fast-growing service company in Remote Patient Monitoring (RPM). The acquisition…
Coala-Life Group AB (publ) (the “Company” or “Coala-Life”) has held an annual general meeting on 30 May 2022. Below follows a summary of the decisions taken by the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the Company’s…
First quarter 2022 Net sales increased to SEK 1.8 M (1.3). EBITDA totaled SEK -26.9 M (-13.0). Operating income totaled SEK -28.0 M (-13.8). Profit after tax was SEK -27.8 M (-13.9). Earnings per share was SEK -0.8 (-6.8). Cash flow from operating activities was SEK -35.4 M (-14.3). Events in the period On February…
The shareholders in Coala-Life Group AB (publ), reg. no. 556495-4682, are hereby given notice to attend the annual general meeting on Monday 30 March 2022. The meeting will be held through postal voting only (see below for more information).
Coala Life announces today that the US Food & Drug Administration (FDA) has cleared additional indications and uses for the Coala Heart Monitor. The new FDA 510k clearance enables the system to be used for auscultation and monitoring of patients’ lungs remotely. The new functionality available is made immediately to…
The subscription period of the rights issue in Coala-Life Group AB (publ) (”Coala-Life Group” or the ”Company”) ended on 11 April 2022. 36,514,460 shares, corresponding to approximately 82.7 percent of the offered shares, were subscribed for by exercise of subscription rights. Additionally, subscription applications corresponding to 2,531,844 shares, equivalent of…
Coala-Life Group AB (publ) (”Coala-Life Group” or the ”Company”), (Nasdaq First North Growth Market: COALA), today publishes a so called EU-growth prospectus in connection with the fully guaranteed rights issue in respect of new shares the terms and conditions of which were announced by the Company through press release on…
The board of directors of Coala-Life Group AB (publ) (”Coala-Life Group” or the ”Company”) has, with the support of the authorisation from the extraordinary general meeting held on 14 March 2022, resolved on a rights issue of approximately 44.2 million shares at a subscription price of SEK 3.40 per share…
Correction refers to incorrect reference to the Market Abuse Regulation, which was removed in this press release: Coala-Life Group AB´s annual report for 2021 is available from today on the company´s website www.coalalife.com.
Coala-Life Group AB´s annual report for 2021 is available from today on the company´s website www.coalalife.com.
At the extraordinary general meeting in Coala-Life Group AB (publ) (the “Company”) held today, on 14 March 2022, the following resolutions were passed in accordance with the proposals presented in the notice to attend the meeting and in the complete proposals on the implementation of incentive programmes kept available at…
The supplement refers to the missing reference to the Market Abuse Regulation, which is now attached to this press release: In connection with the listing on First North 2021, Coala Life announced financial targets to reach sales of SEK 250 million in 2024 with a positive operating profit. The majority…
The shareholders in Coala-Life Group AB (publ), reg. no. 556495-4682, are hereby given notice to attend an extraordinary general meeting at 10:00 a.m. on Monday 14 March 2022. The meeting will be held through postal voting only (see below for more information).
Fourth quarter 2021 Net sales increased to SEK 1.0 M (0.2). EBITDA totaled SEK -118.0 (-15.7). Operating income totaled SEK -120.5 M (-16.5). Profit after tax was SEK -111.0 M (-16.6). Earnings in the period totaled SEK -111.0 M (-16.6). Earnings per share (weighted average) was SEK -6.1 (-8.1). Cash flow from operating activities was…
Coala-Life Group AB (publ) (”Coala-Life Group” or the ”Company”), (Nasdaq First North Growth Market: COALA), hereby announces the Board of Directors’ intention to carry out an issue of new shares of approximately SEK 150 million with preferential rights for the Company’s shareholders (the “Rights Issue”). The Board of Directors will…
The annual report for 2021 will be published on Tuesday, March 15, 2022, against previously communicated time on February 23, 2022. About us Coala Life is a medical device company founded in Sweden focusing on cloud-based cardiac and pulmonary diagnostics. The company has developed and launched the Coala Heart Monitor – a multi-award winning, FDA-cleared…